Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
https://doi.org/10.15829/1728-8800-2021-3010
Abstract
We present a 48-year-old patient with World Health Organization class III idiopathic pulmonary arterial hypertension (IPAH), taking specific therapy with macitentan 10 mg a day, who was readmitted to the National Medical Research Center of Cardiology due to increase in exercise dyspnea and decrease in effort tolerance. According to a comprehensive examination, single factors of high risk and unfavorable prognosis were identified. Due to systemic hypotension when using inhaled iloprost, selexipag was added to therapy. According to control hospitalization, 8-month selexipag therapy improved the patient's condition, as well as high risk factors were not revealed. Selexipag is a selective oral prostacyclin receptor agonist recommended for longterm IPAH therapy in adult patients.
About the Authors
E. A. Rezukhina
National Medical Research Center of Cardiology
Russian Federation
Russian Federation
Elizaveta A. Rezukhina - resident of department of pulmonary hypertension and heart disease of Scientific research institute of clinical cardiology named after A.L. Myasnikov of the National Medical Research Centre of cardiology of Ministry of Health.
Moscow.
Tel.: +7 (917) 535-53-91
O. V. Rodnenkov
National Medical Research Centre of cardiology of Ministry of Health
Russian Federation
Russian Federation
Cardiologist, MD, Senior Research Associate of department of pulmonary hypertension and heart disease of Scientific research institute of clinical cardiology named after A.L. Myasnikov of the National Medical Research Centre of cardiology of Ministry of Health.
Moscow.
T. V. Martynyuk
National Medical Research Center of Cardiology; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
MD, PhD, Head of the Department, Professor of pulmonary hypertension and heart disease of Scientific research institute of clinical cardiology named after A.L. Myasnikov of the National Medical Research Centre of cardiology of Ministry of Health.
Moscow.
References
1. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119. doi:10.1183/13993003.01032-2015.
2. Martynyuk TV. Pulmonary hypertension: diagnosis and treatment. Moscow: LLC “Medical Information Agency”, 2018:304 р. (In Russ.)
3. Chazova I, Martynyuk T, Valieva Z, et al. Clinical and instrumental characteristics of newly diagnosed patients with various forms of pulmonary hypertension according to the Russian National Registry. BioMed Res Int. 2020;2020:6836973. doi:10.1155/2020/6836973.
4. Kylhammar D, Kjellstrom B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-updetermines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-81. doi:10.1093/eurheartj/ehx257.
5. Sitbon O, Channick R, Chin MK, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522-33. doi:10.1056/NEJMoa1503184.
6. Chazova IE, Martynyuk TV, Valieva ZS, et al. Eurasian Guidelines for the diagnosis and treatment of pulmonary hypertension. Eurasian Heart J. 2020;1:78-122. (In Russ.)
7. Galie N, Channick RN, Frantzet RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respiratory J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018.
Supplementary files
Review
For citations:
Rezukhina E.A., Rodnenkov O.V., Martynyuk T.V. Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report. Cardiovascular Therapy and Prevention. 2021;20(5):3010. (In Russ.) https://doi.org/10.15829/1728-8800-2021-3010
Views:
709
Email this article 
